Published in J Biol Chem on July 05, 1990
Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest (1998) 4.00
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol (1998) 1.03
Scatter factor binds to thrombospondin and other extracellular matrix components. Am J Pathol (1996) 0.94
Regulation of thrombospondin1 by extracellular proteases. Curr Drug Targets (2008) 0.89
The role of thrombospondin 1 on intestinal inflammation and carcinogenesis. Biomark Insights (2008) 0.87
Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J (1995) 0.87
Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals (Basel) (2010) 0.78
Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest (1973) 31.28
Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest (1973) 10.18
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet (1995) 7.55
A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. J Clin Invest (1989) 3.71
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A (1997) 3.30
Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N Engl J Med (1997) 3.07
Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region. Cell (1994) 3.06
Isolation of the thrombospondin membrane receptor. J Clin Invest (1987) 2.87
Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A (1974) 2.83
A clinical study of the lupus anticoagulant. Blood (1976) 2.81
Selective removal of albumin from plasma by affinity chromatography. Clin Chim Acta (1973) 2.69
The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A (1998) 2.64
Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure. J Exp Med (1973) 2.56
Isolation and properties of human plasma alpha-1-proteinase inhibitor. Biochemistry (1974) 2.40
Contractile proteins of endothelial cells, platelets and smooth muscle. Am J Pathol (1973) 2.36
Passenger transgenes reveal intrinsic specificity of the antibody hypermutation mechanism: clustering, polarity, and specific hot spots. Proc Natl Acad Sci U S A (1993) 2.30
Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med (1989) 2.21
Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med (1970) 2.21
Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma. Biochem J (1976) 2.15
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Complex formation of platelet thrombospondin with fibrinogen. J Clin Invest (1982) 2.05
Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest (1982) 2.04
Laboratory identification of intravascular coagulation. The serial dilution protamine sulfate test for the detection of fibrin monomer and fibrin degradation products. J Lab Clin Med (1971) 2.04
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Thrombospondin is the endogenous lectin of human platelets. Nature (1982) 1.98
Increased vascular permeability produced by human platelet granule cationic extract. J Clin Invest (1970) 1.98
Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg (1995) 1.96
Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood (1995) 1.94
Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood (1994) 1.90
The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J (1999) 1.88
Binding of plasminogen to cultured human endothelial cells. J Biol Chem (1986) 1.87
Low cytoplasmic mRNA levels of immunoglobulin kappa light chain genes containing nonsense codons correlate with inefficient splicing. EMBO J (1994) 1.87
Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature (1989) 1.85
Targeting of non-Ig sequences in place of the V segment by somatic hypermutation. Nature (1995) 1.80
Cancer and clotting--Trousseau's warning. N Engl J Med (1992) 1.78
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Iodination of the human platelet membrane. Studies of the major surface glycoprotein. J Biol Chem (1973) 1.72
Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med (1986) 1.68
Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood (1994) 1.66
Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc Natl Acad Sci U S A (2001) 1.65
The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A (2000) 1.65
Rabbit platelet bactericidal protein. J Exp Med (1971) 1.63
Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation (1997) 1.62
Subunit structure of factor VIII antigen synthesized by cultured human endothelial cells. J Clin Invest (1975) 1.56
Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes. J Clin Invest (1973) 1.54
Thrombospondin binds to monocytes-macrophages and mediates platelet-monocyte adhesion. J Clin Invest (1987) 1.53
Drug purpura. Semin Hematol (1965) 1.53
Heat-induced fragmentation of human alpha 2-macroglobulin. J Biol Chem (1979) 1.53
Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J Clin Invest (1984) 1.52
Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelial cells. J Exp Med (1987) 1.50
Passive flexion and femoral vein flow: a study using a motorized foot mover. Br Med J (1971) 1.47
Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty. Br J Anaesth (1997) 1.45
Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem (1982) 1.45
Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med (1975) 1.43
Complex formation of platelet thrombospondin with histidine-rich glycoprotein. J Clin Invest (1984) 1.43
Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med (1998) 1.43
Lipoprotein(a) in coronary heart disease. Is it a risk factor after all? JAMA (1994) 1.40
Binding of plasminogen to extracellular matrix. J Biol Chem (1986) 1.38
The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy (1996) 1.38
Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med (1970) 1.38
Human alpha2-macroglobulin. Methods Enzymol (1976) 1.38
Isolation, purification, and partial characterization of platelet membrane glycoproteins IIb and IIIa. J Biol Chem (1981) 1.37
Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem (1991) 1.36
Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun (1992) 1.32
Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest (1989) 1.32
Macrophage plasma membranes. I. Isolation and studies on protein components. J Exp Med (1971) 1.32
Human megakaryocytes. I. Characterization of the membrane and cytoplasmic components of isolated marrow megakaryocytes. J Exp Med (1979) 1.31
Human brain glial cells synthesize thrombospondin. Proc Natl Acad Sci U S A (1986) 1.29
Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood (1981) 1.28
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest (1987) 1.28
Immunoinhibition of ristocetin-induced platelet aggregation. J Clin Invest (1977) 1.26
Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest (1985) 1.24
Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development. EMBO Rep (2000) 1.23
Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem (1985) 1.23
Human platelet activation by C3a and C3a des-arg. J Exp Med (1983) 1.22
Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest (1984) 1.22
Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor. J Biol Chem (1992) 1.21
Immunologic studies of proteins associated with subcellular fractions of normal human platelets. J Lab Clin Med (1967) 1.20
Characterization of human platelet vascular permeability-enhancing activity. J Clin Invest (1972) 1.20
Thrombospondin: a versatile multifunctional glycoprotein. Arteriosclerosis (1986) 1.19
Increased skin permeability in preterm infants. J Pediatr (1971) 1.18
Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest (1981) 1.18
Structural analysis of human platelet membrane glycoprotein I complex. Proc Natl Acad Sci U S A (1979) 1.18
Studies on human platelet protease activity. J Clin Invest (1969) 1.17
Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor. J Clin Invest (1971) 1.16
Somatic mutation of immunoglobulin lambda chains: a segment of the major intron hypermutates as much as the complementarity-determining regions. Proc Natl Acad Sci U S A (1994) 1.16
Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J (2000) 1.15
Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest (1987) 1.15
Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood (1998) 1.15
Gene targeting reveals a crucial role for MTG8 in the gut. Mol Cell Biol (2001) 1.14
Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components. J Lab Clin Med (1974) 1.14